DDInter1417 DDInter1676
Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high binding affinity to the 5-hydroxytryptamine receptor 1A with antagonistic effects. This binding characteristic of penbutolol is being investigated for its implications in Antidepressant Therapy. Penbutolol is contraindicated in patients with cardiogenic shock, sinus bradycardia, second and third degree atrioventricular conduction block, bronchial asthma, and those with known hypersensitivity.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Penbutolol {u} (Compound) resembles {v} (Compound) Timolol
Penbutolol {u} (Compound) resembles {v} (Compound) Bupranolol
Penbutolol {u} (Compound) treats {v} (Disease) hypertension
Penbutolol {u} (Compound) binds {v} (Gene) ORM1
Penbutolol {u} (Compound) causes {v} (Side Effect) Insomnia
Penbutolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Levothyroxine
Penbutolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium oxide
Penbutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calcium citrate
Penbutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Penbutolol {u} may lead to a major life threatening interaction when taken with {v} Dolasetron
Penbutolol (Compound) resembles Timolol (Compound)
Penbutolol (Compound) resembles Bupranolol (Compound)
Penbutolol (Compound) treats hypertension (Disease)
Penbutolol (Compound) binds ORM1 (Gene)
Penbutolol (Compound) causes Insomnia (Side Effect)
Penbutolol may cause a minor interaction that can limit clinical effects when taken with Levothyroxine
Penbutolol may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Penbutolol may lead to a major life threatening interaction when taken with Dolasetron